Abstract: A method for improving productivity in microbial fermentations and mammalian cell culture bioreactors.

Abstract: The invention pertains to method for recovering polycarboxylic acid from an aqueous mixture including the steps of: providing an aqueous mixture including polycarboxylic acid and at least 5 wt. % dissolved halide salt, based on the total weight of water and dissolved material in the aqueous mixture; extracting the polycarboxylic acid from the aqueous mixture into a first organic liquid including an organic solvent selected from the group consisting of ketones and ethers, thereby obtaining an organic polycarboxylic acid solution and an aqueous waste liquid including the halide salt; and extracting the polycarboxylic acid from the organic carboxylic acid solution into an aqueous liquid, thereby obtaining an aqueous polycarboxylic acid solution and a second organic liquid. The method according to the invention allows a combined purification and concentration step for feed solutions of polycarboxylic acids.

Abstract: Provided herein are methods of culturing a microorganism. The methods include providing a container comprising one or more microorganisms in a medium, which has a first carbon to nitrogen ratio; culturing the microorganisms until the culture reaches a threshold indicator; harvesting a portion of the culture while maintaining the majority of the culture in the container; and adding fresh medium comprising a second carbon to nitrogen ratio to the container with the majority of the culture comprising the microorganisms.

Abstract: Provided is a large-scale cell culture system for producing products without harming animals. Also provided is a method for making meat products using this cell culture system. Further provided is a method for making personal care products using this cell culture system, as well as a method for making nutritional supplements using this cell culture system.

Abstract: A process for hydrolyzing lignocellulosic biomass includes feeding lignocellulosic biomass into a pretreatment reactor, wherein the pretreatment reactor has a headspace charged with sulfur dioxide previously used in the pretreatment of lignocellulosic biomass. In addition, acid comprising sulfur dioxide and/or sulfurous acid is fed into the pretreatment reactor (e.g., with the lignocellulosic biomass, separate from the lignocellulosic biomass, or a combination thereof) and the lignocellulosic biomass is heated. As the pretreated lignocellulosic biomass is discharged from the pretreatment reactor, at least a portion of the sulfur dioxide used in the pretreatment is retained in the headspace.

Abstract: The present invention relates to the co-production and isolation of mycoprotein and ethanol from carbohydrate feedstock material (e.g cereals). The present invention also provides a fermentation system for the co-production of mycoprotein from a carbohydrate feedstock material.

Abstract: The present invention relates to a process for the production of second generation biofuels and/or sugar based chemicals—for example ethanol, butanol etc—and/or materials—for example plastics, single cell proteins etc.—together with sulfonated lignin from lignocellulosic biomass, in particular from lignocellulosic biomass comprising, among others, annual plants, agricultural waste, or wood. In particular, the present invention relates to a process for the production of sugar based chemicals, biofuels or materials together with sulfonated lignin from lignocellulosic biomass comprising the pretreatment of a lignocellulosic biomass in a sulfite cooking step.

Abstract: In vitro and in vivo application of sub-atmospheric, negative pressure on growth factor starting material, such as whole blood, extracts growth factors from the platelet granules of the growth factor starting material in a non-destructive medium without activating the clotting process. The extracted growth factors are released into a growth factor composition containing blood plasma, extracellular fluid or interstitial fluid depending upon the type and location of the growth factor starting material. The growth factors have a weight of about 70-76 kDaltons and are applied in either a filtered or unfiltered state topically to the area of a surface wound to effect healing. The extracted growth factors are also injected into soft tissue, such as a torn tendon, to promote tissue growth and healing. The growth factors are released in one method from a patient's own blood. In another method the growth factors are released from a whole blood source and freeze dried by lyophilization.

Abstract: Certain embodiments are directed to sensors that enable the use of optimized biocompatible materials such as pre-anodized paper printed electrode transducer to detect binding of a target agent, wherein the surface is modified or functionalized through zero length cross-linker so that it interacts with or specifically binds a target such as sugars (glucose) or glycated proteins (HgbA1c).

Abstract: A pharmaceutical composition includes an effective amount of a bio-active fraction or subfraction of lyophilized camel urine. The composition is used as an anti-cancer drug which selectively targets the cancer cells without affecting the normal cells.

Abstract: The present invention relates to a method for cultivating in vitro in an acellular culture medium, bacteria for which the growth is sensitive to oxygen content, said bacterium being selected from anaerobic bacteria and intracellular micro-aerophilic bacteria, characterized in that uric acid is added into said acellular culture medium, and said bacterium is cultivated in said culture medium in the presence of oxygen.

Abstract: The present disclosure provides a composition and method for promoting functional neuronal development in pediatric subjects. The composition comprises in some embodiments up to about 7 g/100 Kcal of a fat or lipid source; up to about 5 g/100 Kcal of a protein source; about 3 mg/100 Kcal to about 50 mg/100 Kcal of phosphatidylethanolamine; about 0.15 mg/100 Kcal to about 75 mg/100 Kcal of sphingomyelin; and about 5 mg/100 Kcal to about 75 mg/100 Kcal of docosahexaenoic acid. The methods comprise, in some embodiments, administering the aforementioned composition to a pediatric subject.

Abstract: Provided is a composition containing Bifidobacterium for alleviating, preventing or treating rheumatoid arthritis. The Bifidobacterium bifidum ATT newly isolated according to the present invention is useful as a rheumatoid arthritis medicine or a probiotic material for alleviating rheumatoid arthritis owing to potent efficacy in treating rheumatoid arthritis.

Abstract: The invention relates to a method for reducing colour of a biotechnological liquid. In the method a biotechnological liquid comprising colour forming substances is obtained and a high-basicity aluminium compound, which has a basicity of at least 0%, is added and mixed to the biotechnological liquid. Precipitate and/or flocks comprising colour forming substances are allowed to form, and the precipitate and/or flocks are separated from the biotechnological liquid.

Abstract: The present invention provides a pharmaceutical composition and a food composition for preventing or treating lipid-related metabolic disease, which contain, as active ingredients, probiotics and a vitamin B complex. When the composition comprising the probiotics and the vitamin B complex is used, it may further promote in vivo absorption of the vitamin B complex, and may induce a synergistic effect on a reduction in blood lipid levels, thereby exhibiting an effect on the alleviation, prevention or treatment of obesity and lipid-related metabolic disease.

Abstract: Embodiments described herein are directed to devices for supporting growth of anisotropic muscle tissue layers and in vitro readout and quantification of force generated by the tissue layers using one or more strain-sensing elements integrated into the device. Embodiments also include multiplexed apparatuses of multiple independent devices, methods of fabricating the devices and apparatuses, and methods of using the devices and apparatuses.

Abstract: A method is provided for treating a Mendelian disorder of the epigenetic machinery (e.g., Kabuki syndrome) in a subject in need thereof. In particular, the method comprises administering to the subject a ketogenic composition in an amount sufficient to produce a physiologically acceptable ketosis in the subject. A method for selecting a subject for treatment of a Mendelian disorder of the epigenetic machinery (e.g., Kabuki syndrome) is also provided. Ketogenic compositions and kits useful for practicing the methods are also provided.

Abstract: A low-cost process is provided to render lignocellulosic biomass accessible to cellulase enzymes, to produce fermentable sugars. Some variations provide a process to produce ethanol from lignocellulosic biomass (such as sugarcane bagasse or corn stover), comprising introducing a lignocellulosic biomass feedstock to a single-stage digestor; exposing the feedstock to a reaction solution comprising steam or liquid hot water within the digestor, to solubilize the hemicellulose in a liquid phase and to provide a cellulose-rich solid phase; refining the cellulose-rich solid phase, together with the liquid phase, in a mechanical refiner, thereby providing a mixture of refined cellulose-rich solids and the liquid phase; enzymatically hydrolyzing the mixture in a hydrolysis reactor with cellulase enzymes, to generate fermentable sugars; and fermenting the fermentable sugars to produce ethanol. Many alternative process configurations are described.

Abstract: The present invention relates to novel isolated bacterial strains, which are members of the genus Paenibacillus, originally isolated from soil and showing antagonistic activity against a broad range of pathogens and being capable of producing antimicrobial metabolites. It was found that the strains Lu16774 and Lu17007 belong to a novel subspecies named Paenibacillus polymyxa ssp. plantarum while the strain Lu17015 belongs to a novel species which is proposed to be Paenibacillus epiphyticus. The present invention also relates to microbial pesticide compositions comprising at least one of such novel bacterial strains, whole culture broth or a cell-free extract or a fraction thereof or at least one metabolite thereof, and/or a mutant of at least one of said novel bacterial strains having all the identifying characteristics of the respective bacterial strain or whole culture broth, cell-free extract, fraction and/or metabolite of the mutant thereof showing antagonistic activity against plant pathogens.

Abstract: The invention relates to use of a bacterium selected from a lactic acid bacterium, a Bifidobacterium or a mixture of any thereof for treating metabolic endotoxemia, inhibiting bacterial translocation and regulating lipid absorption in a mammal.